Clinical trials: Elevated Blood Pressure
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Glaucoma, Ocular Hypertension
A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
A one month study which will determine the safety and efficacy of bimatoprost eye drops in patients with glaucoma or ocular hypertension
- Trial name
- NCT00538304
- Testing
- bimatoprost eye drops
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Allergan
Severe Hypertension
Study of CS-3150 in Patients With Severe Hypertension
To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).
- Trial name
- NCT02808026
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hypertension
Atacand (Candesartan) Real Life Study
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records.
- Trial name
- Real Life (NCT00620178)
- Testing
- Candesartan Cilexetil, Losartan
- Where
- Sweden
- Volunteers
- 14,000 people
- Sponsor
- AstraZeneca
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Hypertension
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
The objective was to evaluate and compare the pharmacokinetic profiles and safety after administration of test drug (CKD-341) and reference drugs (D956) in healthy adults.
- Trial name
- NCT06281132
- Testing
- CKD-341, D956
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure…
- Trial name
- GMRx2_PCT (NCT04518306)
- Testing
- Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Where
- 47 sites in United States, Australia and 3 more
- Volunteers
- 755 people
- Sponsor
- George Medicines PTY Limited
Open-angle Glaucoma, Ocular Hypertension
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or…
- Trial name
- NCT04499248
- Testing
- AGN-193408 SR, Lumigan, Lumigan Vehicle
- Where
- 49 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- AbbVie
Open Angle Glaucoma, Ocular Hypertension
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
- Trial name
- NCT06666855
- Testing
- DE-117B Eye Drops, Latanoprost
- Where
- 24 sites in China
- Volunteers
- 345 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
This is an open-label, single-arm, Phase Ⅰa clinical study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of multiple doses of Telpegfilgrastim Injection in non-pregnant…
- Trial name
- NCT06924385
- Testing
- Telpegfilgrastim Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Hypertension
Controlling And Lowering Blood Pressure With the MobiusHDTM Device
To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.
- Trial name
- CALM-START (NCT02804087)
- Testing
- MobiusHD
- Where
- 4 sites in Netherlands
- Volunteers
- 4 people
- Sponsor
- Vascular Dynamics, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular…
- Trial name
- NCT00465621
- Testing
- Xalatan
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Alcon Research
Hypertension
A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers
The purpose of this study is to evaluate pharmacokinetic interactions and safety between fimasartan and linagliptin in healthy male volunteers.
- Trial name
- NCT03250052
- Testing
- (fimasartan or linagliptin) x 7days, (fimasartan and linagliptin) x 7days
- Where
- South Korea
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of amlodipine(5mg or 10mg) and losartan (50 mg or 100 mg), amlodipine and losartan alone in reducing blood pressure.
- Trial name
- NCT00942344
- Testing
- Amlodipine plus Losartan, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
1QG2 is a Phase 1 study aiming to assess the safety and tolerability of ascending single/multiple oral doses (SAD \& MAD) in healthy young subjects, the preliminary food interaction and the effect of QGC001 on blood pressure and…
- Trial name
- NCT01900184
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary…
- Trial name
- MOMENTOUS (NCT06911632)
- Testing
- ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
- Where
- 41 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Glaucoma
24-hr Intraocular Pressure Control With SIMBRINZA ®
The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.
- Trial name
- NCT02770248
- Testing
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Vehicle
- Volunteers
- 162 people
- Sponsor
- Alcon Research
Pulmonary Hypertension Associated With Sickle Cell Disease
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell…
- Trial name
- NCT03055234
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Essential Hypertension
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the…
- Trial name
- NCT02944734
- Testing
- Candesartan Cilexetil 8mg, Candesartan Cilexetil 16mg, Amlodipine 5mg
- Where
- 23 sites in South Korea
- Volunteers
- 392 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.